Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.3
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash $ 836,034 $ 270,884
Prepaid income taxes 29,127
Prepaid expenses 35,840
Total current assets 901,001 270,884
Investments held in Trust Account 50,671,661 118,165,948
Total Assets 51,572,662 118,436,832
Current liabilities:    
Accounts payable and accrued expenses 86,362 94,720
Franchise and income taxes payable 82,317
Convertible promissory note - related party 412,301
Promissory note - CannBioRx 942,870
Promissory note - Tyche Capital LLC 650,000
Advances due - related party 696,926 369,030
Total current liabilities 2,788,459 546,067
Deferred underwriting fees 4,025,000 4,025,000
Total Liabilities 6,813,459 4,571,067
Commitments and Contingencies
Common stock, $0.0001 par value subject to possible redemption; 3,867,626 and 10,778,788 shares as of September 30, 2019 and December 31, 2018, respectively (at approximately $10.28 and $10.10 per share) 39,759,195 108,865,759
Stockholders' Equity:    
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding as of September 30, 2019 and December 31, 2018
Common stock, $0.0001 par value; 35,000,000 shares authorized; 4,300,589 and 4,098,712 shares issued and outstanding (excluding 3,867,626 and 10,778,788 shares subject to possible redemption, respectively) as of September 30, 2019 and December 31, 2018, respectively 430 410
Additional paid-in capital 3,639,402 3,838,395
Retained earnings 1,360,176 1,161,201
Total Stockholders' Equity 5,000,008 5,000,006
Total Liabilities and Stockholders' Equity $ 51,572,662 $ 118,436,832